Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

Abstract Background Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer’s disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such as dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD), is...

Full description

Bibliographic Details
Main Authors: Ross W. Paterson, Catherine F. Slattery, Teresa Poole, Jennifer M. Nicholas, Nadia K. Magdalinou, Jamie Toombs, Miles D. Chapman, Michael P. Lunn, Amanda J. Heslegrave, Martha S Foiani, Philip S. J. Weston, Ashvini Keshavan, Jonathan D. Rohrer, Martin N. Rossor, Jason D. Warren, Catherine J. Mummery, Kaj Blennow, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Cerebrospinal fluid
Biomarkers
Alzheimer’s disease
Differential diagnosis
Online Access:http://link.springer.com/article/10.1186/s13195-018-0361-3

Internet

http://link.springer.com/article/10.1186/s13195-018-0361-3

Similar Items